The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism. Mergers, Acquisitions and Divestitures, United States Politics and Government, Tylenol (Drug), Autism, Suits and Litigation (Civil), Regulation and Deregulation of Industry, Labeling and Labels (Product), Food and Drug Administration, Johnson & Johnson, Kenvue Inc, Kimberly-Clark Corporation, Kennedy, Robert F Jr, Trump, Donald J Read More
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
